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Matched unrelated donor (MUD) transplantation is the ﬁrst alternative in the absence of a matched sibling
donor. For patients without a suitable adult donor, we have adopted the dual stem cell transplantation
protocol consisting of cord blood (CB) in combination with CD34þ cells from a third party HLA-mismatched
donor. We analyzed the outcomes of patients undergoing both procedures in a single center. Starting in 2004,
a total of 20 patients with high-risk disease underwent 22 dual transplants and 25 patients underwent
myeloablative MUD transplantation. The 30-day cumulative incidence of neutrophil engraftment was similar
in both groups (91% and 95%), with a median time to engraftment of 14 and 16 days, respectively. Grade II-IV
acute graft-versus-host disease was more frequent in the MUD group (40% versus 5%). Except for a tendency
toward a higher incidence of viral hemorrhagic cystitis in the dual transplantation group, posttransplantation
infectious events were comparable in the 2 groups. The 3-year cumulative incidence rates of relapse (41%
versus 44%) and nonrelapse mortality (30% versus 25%) were similar in the MUD and dual transplantation
cohorts. Estimated 3-year overall survival and disease-free survival were 47% and 41%, respectively, with no
survival advantage for either group. In our experience, dual transplantation offers survival rates comparable
to those from myeloablative MUD transplantation with similar nonrelapse mortality rates.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION The objective of this study was to analyze toxicity and
In the absence of an HLA-matched sibling donor, an
unrelated adult donor (MUD) matched at 8 of 8 alleles for
HLA-A, -B, -C, and -DRB1 is considered the ﬁrst alternative for
allogeneic stem cell transplantation (SCT). However, only 50%
of patients have a suitable donor in a median of 4 months in
Europe [1]. Unrelated umbilical cord blood (CB) is being
increasingly used as an alternative stem cell source for adult
patients eligible for allogeneic SCT but lacking an HLA-
matched adult donor [2-4]. Late engraftment, with the
subsequent increased risk of serious early neutropenia-
related infections, prolonged length of hospital stay, and
high nonrelapsemortality (NRM), are considered some of the
main limitations of CB transplantation [5,6]. To overcome
these drawbacks, which are related mainly to the limited
number of cells available in a single unit, several strategies
have been explored, including CB in vitro culture expansion,
double CB transplantation, and direct intrabone trans-
plantation of CB cells [7-10]. In this context, single CB trans-
plantation with the coinfusion of mobilized and selected
CD34þ cells from a third party HLA-mismatched donor (TPD),
known as dual SCT, has been shown to reduce the period
of posttransplantation neutropenia and related early
morbidity and mortality associated with single CB trans-
plantation [11-15].dgments on page 148.
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12.08.019survival rates of adults who underwent dual SCT in our
center and to compare these rates with those in a cohort of
patients who underwent myeloablative MUD SCT in our
center in the same time period.
PATIENTS AND METHODS
Eligibility
The study was approved by the hospital’s Institutional Review Board,
and all donors and recipients gave written informed consent. The study
population included consecutive adult patients with high-risk hematologic
disease who underwent dual or myeloablative MUD SCT from March 2004
and had a minimum posttransplantation follow-up of 6 months.
Graft Selection and Processing
For CB units, a match of at least 4 of 6 HLA loci, considering low reso-
lution for HLA-A and HLA-B and high resolution for HLA-DR, was required.
CB units were selected based on total nucleated cell (TNC) dose and CD34þ
and HLA matching as determined before freezing, focusing on cell dose at
the expense of matching. CB units with higher cryopreserved cell doses after
volume reduction, with a minimum of 2  107 TNCs/kg and 1  105 CD34þ
cells/kg, were preferred. ABO compatibility was a secondary selection
criterion.
Donors of the HLA-mismatched CD34þ cells were sought from among
each patient’s ﬁrst-degree relatives. Given the reported high incidence of
graft failure related to the use of maternal donors [11,12], nonmaternal
relatives were preferred. If no relatives were available, then an unrelated
individual was selected as the donor. Granulocyte colony-stimulating factor,
10 mg/kg/day, was administered for 4 consecutive days to all donors, and
cells were collected with a continuous-ﬂow apheresis device. CD34þ cells
were selected by a positive immunomagnetic technique (CliniMACS; Mil-
tenyi Biotec, Cologne, Germany) to obtain a ﬁnal product with 2.5-3  106
CD34þ cells/kg and <1  104 CD3þ cells/kg of recipient body weight, as
described previously [11,12].
Within the MUD cohort, donors were identiﬁed by the Spanish national
donor registry (REDMO) to have at least 8/8 high-resolution HLA matching
at loci A, B, C, and DRB1. Males or females without a history of previousTransplantation.
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bility were preferred. For cytomegalovirus (CMV)-negative patients,
CMV-negative donors were preferable.
Conditioning Regimen and Graft-versus-Host Disease Prophylaxis
The conditioning regimen for dual SCT included ﬂudarabine 30 mg/m2
(days 8 to 5), antithymocyte globulin (ATG) 2 mg/kg (days 2 and 1),
cyclophosphamide 60 mg/kg (days 4 and 3), and i.v. busulfan 3.2 mg/kg
(days6 and5) (oral busulfan 4mg/kg uo to 2006) or 10 Gy of fractionated
total body irradiation (TBI). CB cells were infused on day 0, followed by the
TPD cells either the same day or on day þ1 posttransplantation. As graft-
versus-host disease (GVHD) prophylaxis, patients received cyclosporine
(CsA) from day 5, ﬁrst i.v. and then orally, and metilprednisolone 2 mg/kg
from day 2 and tapered until suspension on day þ10. In the absence of
GVHD manifestations, CsA was tapered from day þ60.
Conditioning for MUD transplantation included i.v. busulfan 3.2 mg/kg
for 4 days (except for 1 patient who received oral busulfan) and either
cyclophosphamide 60 mg/kg (days 3 and 2), ﬂudarabine 40 mg/m2 for 4
days, or 12 Gy of fractionated TBI. ATG 2.5mg/kg on days3,2, and1was
included in all but 2 MUD transplantations. GVHD prophylaxis was provided
by CsA starting on day 7 and a short course of methotrexate (15 mg/m2 on
day þ1 and 10 mg/m2 on days þ3, þ6, and þ11) . In the absence of GVHD
manifestations, CsA was tapered starting on day þ60.
Supportive Care
Patients were housed in high-efﬁciency particulate aireﬁltered rooms.
Patients undergoing dual SCT received granulocyte colony-stimulating
factor, 5 mg/kg/day s.c., from day þ1 until neutrophil recovery. All dual
and MUD SCT recipients received oral quinolone as antibacterial prophy-
laxis. Prophylaxis against Pneumocystis jiroveci consisted of cotrimoxazole
(320/1600 mg sulfamethoxazole/trimethoprim daily) from day 7 to
day2, then resumed after engraftment andmaintained for aminimum of 1
year. Intravenous itraconazole 200 mg/day or micafungin 50 mg/day (since
2010) were administered as antifungal prophylaxis. Acyclovir was used as
anti-herpesvirus prophylaxis. Galactomannan testing and CMV polymerase
chain reaction analysis were performed twice weekly, and Epstein-Barr
virus (EBV) polymerase chain reaction analysis was performed every other
week until day þ100 or indeﬁnitely for those with active GVHD. All blood
products were irradiated and leukocyte-depleted. Nonspeciﬁc i.v. immu-
noglobulin was administered at a dose of 400 mg/kg every 2-3 weeks from
day þ7 until hospital discharge and then monthly during the ﬁrst 100 days
after transplantation.
Pretransplantation and Posttransplantation Evaluation
Response to therapy before and after transplantation was evaluated
based on the National Cancer Institute’s criteria as revised by the Interna-
tional Working Group for the Diagnosis, Standardization of Response
Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic
Trials in Acute Myeloid Leukemia [16]. Comorbidities were recorded using
the hematopoietic cell transplantationespeciﬁc comorbidity index [17].
Posttransplantation bone marrow (BM) analysis and disease restaging were
repeated routinely on days þ30, þ100, þ180, and þ365 and yearly there-
after, and whenever clinically indicated.
Chimerismwas determined by molecular analysis in BM and peripheral
blood (PB). BM samples were analyzed on days þ30, þ100, þ180, þ365, and
once yearly thereafter. PB samples were obtained once a week starting on
day þ14 in patients with mixed chimerism (MC), once a month during the
ﬁrst year posttransplantation and every other month thereafter. Donor and
recipient cells were detected by quantitative analysis of informative
microsatellite DNA polymorphisms as described previously [18].
Acute GVHD (aGVHD) was scored according to published consensus
criteria [19]. Chronic GVHD (cGVHD) was scored according to the National
Institutes of Health’s Consensus Development Project [20].
Deﬁnitions
Myeloid engraftment was deﬁned as an absolute neutrophil count of
0.5  109/L for 3 consecutive days. Platelet engraftment was deﬁned as
a platelet count of 20  109/L, without transfusion support, for 3 consec-
utive days. Patients who survived more than 30 days after transplantation
and who failed to achieve myeloid engraftment were considered graft fail-
ures. Diagnosis of disease recurrence was based on clinical and pathological
criteria.
Statistical Analysis
Quantitative variables are expressed as median and either range or
interquartile range (IQR). Qualitative variables are expressed as frequency
and percentage. The Fisher exact test or the c2 test were used to test for the
association between qualitative variables. Comparability of the 2 cohorts(dual andMUD) for themain prognostic features was tested with either the t
test or the Mann-Whitney U test, depending on normality and variance
assumptions.
NRM, disease relapse or progression, overall survival (OS), and disease-
free survival (DFS) were deﬁned as primary endpoints. NRM was deﬁned as
death from any cause without previous disease relapse or progression. OS
was deﬁned as the time from transplantation to death from any cause, and
surviving patients were censored at last follow-up or at time of subsequent
transplantation [21,22]. For those patients with graft failure and rescued
with a subsequent transplantation, follow-up was measured from the date
of ﬁrst transplantation until death or last follow-up. DFS was deﬁned as the
time from transplantation to relapse, disease progression, or death from any
cause, whichever occurred ﬁrst. Estimates of DFS and OS were calculated
using the Kaplan-Meier method, including 95% conﬁdence interval (CI), and
differences between both cohorts were compared using the 2-tailed log-
rank test.
Estimates of engraftment, NRM, and relapse or progression after
transplantation were calculated using cumulative incidence rates and
compared by univariate Cox regression. Patient follow-up was updated on
April 2012.
RESULTS
Patients
Twenty consecutive adult patients with high-risk hema-
tologic disease who did not have an available HLA-identical
related or unrelated donor underwent a total of 22 dual
SCTs between March 2004 and May 2011. These patients had
a median weight of 70.5 kg (IQR, 56-76 kg). During the same
time period, 25 consecutive patients with similar pre-
transplantation characteristics underwent myeloablative
allogeneic MUD SCT. Characteristics of both groups are
summarized in Table 1.
In the dual SCT group, 12 patients (60%) underwent SCT in
ﬁrst complete remission (CR1) and 6 patients (30%) had
active disease. Eighteen dual SCTs were performed with the
busulfan-based preparative regimen, and 2 patients with
acute lymphoblastic leukemia received TBI-based condi-
tioning. In addition, 2 patients who exhibited primary CB
graft failure were rescued with a second dual SCT using
thiotepa, ﬂudarabine, and ATG as the conditioning regimen.
Within the MUD group, 11 patients (44%) underwent SCT
in CR1 and 10 (40%) had active disease. Five patients, 3 of
them with acute lymphoblastic leukemia, received TBI as
part of their conditioning regimens. Patient characteristics
were not statistically different between the 2 groups
(Table 1).
Graft Features
In the dual SCT group, the median number of post-
processing CB TNCs and CD34þ cellswere 2.8 107/kg (range,
1.48-4.74107/kg) and 1.7105/kg (range, 0.73-3.2105/kg),
respectively (Table 1). The HLA-mismatched TPDwas a sibling
(in 62%,14%of them fullymismatched), another haploidentical
relative (father in13%, son in9%, andmother in1case), ora fully
mismatched unrelated individual (in 1 case). The median
number of infused TPD CD34þ cells was 2.6  106/kg (range,
1.5-3.2  106/kg), and the median number of CD3þ cells was
0.23  104/kg (range, 0.05-1.5  104/kg).
In theMUD group, the stem cell sourcewas BM in 32% and
mobilized PB in 68%. All patients received a 12/12 HLA
alleleematched graft. The median number of infused TNC
and CD34þ cells was 4.8  108/kg (range, 0.8-16 108/kg)
and 4  106/kg (range, 0.8-19  106/kg), respectively.
Engraftment and Chimerism
In the dual SCT group, the cumulative incidence of
myeloid engraftment at 30 days was 91% (Figure 1), with
a median time to engraftment of 14 days (range, 9-28 days).
Table 1
Characteristics of Patients and Transplants
Characteristic MUD (n ¼ 25) Dual (n ¼ 20) P Value
Patients
Age, years, median (IQR) 38 (30-52) 39 (28-49) .79
Sex, n (%)
Male 16 (64) 11 (55) .55
Female 9 (36) 9 (45)
Disease status at transplantation, n (%)
Acute myelogenous leukemia/myelodysplastic syndrome 18 (72) 11 (55)
CR1 7 (28) 8 (40) .12
Other 11 (44) 3 (15)
Acute lymphoblastic leukemia 4 (16) 6 (30)
CR1 3 (12) 3 (15) .57
Other 1 (4) 3 (15)
Lymphoproliferative disease 2 (8) 2 (10) .77
Chronic myelogenous leukemia 1 (4) 1 (5) .57
Previous transplantation, autologous/allogeneic, n (%) 3 (12)/1 (4) 2 (10)/0 (0) .68
Time from diagnosis to transplantation months, median (IQR)* 9 (6-14) 8 (6-9) .11
HCT-CI, n (%)
0-2 24 (96) 20 (100) 1
3 1 (4) 0 (0)
Transplants
ABO blood group mismatch, n (%)
Major 10 (40) 5 (22)
Minor 2 (8) 3 (13)
None 13 (52) 14 (63)
Conditioning, n (%)
Busulfan-ﬂudarabine 13 (52) 0
TBI-containing regimen 5 (20) 2 (9)
Busulfan-ﬂudarabine-cyclophosphamide 0 18 (82)
ATG-containing regimen 23 (92) 22 (100)
GVHD prophylaxis, n (%)
CsA þ methotrexate 24 (96) 0
CsA þ steroids 0 20 (90)
CsA þ/ mycophenolate mofetil 0 2 (8)
CB cells, median (range)y
TNCs  107/kg - 2.8 (1.48-4.74)
CD34þ  105/kg - 1.7 (0.73-3.2)
TPD cells, median (range)z
CD34þ  106/kg - 2.6 (1.5-3.2)
CD3þ  104/kg - 0.23 (0.05-1.5)
MUD cells, median (range)z
TNCs  108/kg 4.8 (0.8-16) -
CD34þ  106/kg 4 (0.8-19) -
HLA match, n (%)
8/8 25 (100) -
6/6 - 0
5/6 - 4 (18)
4/6 - 18 (82)
HCT-CI indicates Hematopoietic Cell Transplantation Comorbidity Index.
* Patients in CR1.
y After processing and before cryopreservation.
z Infused cells.
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78%, with a median time of platelet engraftment of 27 days
(range, 9-84 days). All patients exhibited PB MC on days þ7
and þ14, with varying percentages of CB and TPD cells.
At 2 months after transplantation, 82% (14 of 17) of
evaluable patients exhibited full PB CB chimerism,whichwas
reached in a median of 24 days (range, 13-67 days). All 14
patients had full sustained CB engraftment on the last follow-
up. Two of the 3 remaining patients experienced CB graft
failure. The third patient exhibited MC during the ﬁrst 2
months with variable proportions of recipient, CB, and TPD
cells; however, TPD was not detected at 2 months post-
transplantation, and the patient remained in MC with
increasing percentages of recipient cells until relapse (at 4
months posttransplantation).
CB graft failure was documented in 3 patients in the dual
SCT group (13%). Two of these patients showed engraftment
of TPD cells only. One of these patients died due to toxicityand infection after a second CB transplantation (despite CB
myeloid engraftment), and the other patient died due to
relapse after multiple infectious complications stemming
from poor immune reconstitution. Of note, the 2 patients
with persistent TPD neutrophil engraftment experienced
severe infectious complications due to poor immune recon-
stitution. The third patient demonstrated failure of both graft
sources and underwent a second dual SCT on day þ43, with
a favorable outcome. In these 3 patients, CB CD34þ cell and
TNC content met cellularity criteria, and retrospective anal-
ysis of HLA antibody detection was negative. Postthaw
growth of colony-forming units (CFU) was poor in 1 of the 3
patients with CB graft failure cases (23  104) and was not
detected in the other 2 patients.
In the MUD group, 1 patient (4%) had primary graft
failure with early relapse. The remaining 24 patients expe-
rienced myeloid engraftment at a median of 16 days post-
transplantation (range, 12-28 days) and platelet engraftment
Figure 1. Cumulative incidence of neutrophil (A) and platelet (B) engraftment in dual SCT and MUD SCT recipients.
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incidence of 95% at 30 days and 87% at 60 days, respectively.
GVHD
The cumulative incidence of grade II-IV aGVHD at
day þ100 was 5% in the dual SCT group and 40% in the MUD
group (Figure 2). Grade III-IV aGVHD was present in 6
patients in the MUD group but in no patients in the dual SCT
group.
cGVHDwas documented in 3 of 11 patients (27%) at risk in
the dual SCT group and in 8 of 14 patients (57%) in the MUD
group. Nevertheless, the 2-year cumulative incidence of
moderate-severe cGVHD was 8% in the dual SCT group and
21% in the MUD group (P ¼ .37). In addition, 3 patients from
the MUD group developed severe GVHD after rapid with-
drawal of immunosuppression in 2 patients and donor
lymphocyte infusion in 1 patient, which were performed
because of relapse and increasing MC.
Survival and Relapse
With a median follow-up of 36 months (IQR, 19-75
months) for the entire cohort, 36months (IQR,13-88months)
for the dual SCT group, and 34 months (IQR, 20-68 months)
for the MUD group, estimated 3-year OS and DFS were 47%Figure 2. Cumulative incidence of grade II-IV aGVHD (A) and moder(95% CI, 32%-62%) and 41% (95% CI, 27%-56%), respectively
(Figure 3). Differences in OS and DFS between the 2 groups
were not statistically signiﬁcant (Figure 3).
The cumulative incidence of relapsewas44% at both 1 year
and 3 years in the dual SCT group and 35% at 1 year and 41%
at 3 years in the MUD group (P ¼ .92). For the entire cohort,
the cumulative incidence of relapse at 3 years was 34% for
patients undergoing SCT in CR1 and 57% in those undergoing
SCT with active disease. No patient in either group experi-
enced relapse beyond 2 years posttransplantation (Figure 3).
NRM, Infections, and Hospital Stay
Most of the transplantation-related deaths occurred
within the ﬁrst year after transplantation, with no signiﬁcant
differences in the cumulative incidence of NRM between the
2 groups (P ¼ .79) (Figure 3). A tendency toward a higher
incidence of viral hemorrhagic cystitis was seen in the dual
SCT group compared with the MUD group (31% versus 8%;
P ¼ .08). The remaining infectious events in the ﬁrst 100
days after SCT showed similar incidence rates in the dual SCT
and MUD groups, including probable and proven fungal
infections (10% versus 12%) and CMV reactivation (77%
versus 76%). Using a preemptive therapy approach, no
signiﬁcant CMV disease incidence or CMV-related deathsate to severe cGVHD (B) in dual SCT and MUD SCT recipients.
Figure 3. DFS (A), cumulative incidence of relapse (B), cumulative incidence of NRM (C), and OS (D) in dual SCT and MUD SCT recipients.
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phoproliferative disease (PTLD) were documented, 1 treated
successfully with rituximab in the dual SCT group and the
other requiring chemotherapy with R-CHOP (rituximab,
cyclophosphamide, hydroxydaunorubicin, ocovin, and
prednisone) and immunosuppression withdrawal with fatal
evolution in the MUD group. In addition, 1 case of EBV
reactivation without PTLD documentation occurred and was
well controlled in the MUD group.
The median number of hospitalization days during the
ﬁrst 6 months after transplantation was 64 days (IQR, 39-82
days) for the dual SCT group and 49 days (IQR, 32-92 days)
for the MUD group (P ¼ .59).
DISCUSSION
Umbilical CB from unrelated donors is being increasingly
used as an alternative stem cell source for adult patients with
hematologic malignancies lacking an HLA-matched adult
donor [2-5]. Comparisons of standard single CB SCT with
MUD SCT in registry studies have shown comparable DFS in
the 2 groups, with lower GVHD rates but higher NRM in the
CB recipients [5].
Several strategies are being explored in the setting of CB
transplantation to overcome the complications derived from
delayed myeloid engraftment. In our institution, we have
adopted the dual strategy of coinfusion of mobilized andselected CD34þ cells from a third party HLA-mismatched
donor together with a single CB unit for allogeneic SCT
candidates without a suitable HLA-matched adult donor
[11-15]. This approach offers the advantage of rapid engraft-
ment of the TPD cells, reducing the risk of early infections,
followed by sustained hematopoietic engraftment of the CB.
In fact, it provides the most rapid neutrophil engraftment
reported among different CB transplantation modalities
[3,7-10]. A single-center comparative study including dual
SCT for patients with acute leukemia and myelodysplastic
syndromes showed comparable DFS and OS as myeloablative
SCT fromHLA-identical relateddonors [15]. Thedual platform
also has been recently adopted by other groups for patients
with aplastic anemia [23] and patients with high-risk hema-
tologic disorders using reduced-intensity conditioning [24],
with similar results in termsof both engraftment and survival.
Nevertheless, cumulative experience with this CB trans-
plantation modality remains scarce. Our single-center study
provides 2 unique aspects compared with previous reports:
(1) a comparison with myeloablative MUD transplants,
considered the standard of care for patients with indications
for allogeneic transplantation lacking an HLA-identical
sibling, and (2) a long-term follow-up of the series (3 years).
Patient features werewell balanced between the 2 groups
in terms of demographic features, previous transplantation,
comorbidities, and time from diagnosis to transplantation
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regarding speciﬁc diagnosis and disease status at trans-
plantation were noted, possibly owing to the limited sample
size. Nevertheless, these potential speciﬁc differences are not
critical, given that the vast majority of cases involve high-risk
patients with acute leukemia in both groups, making pre-
transplantation characteristics comparable in the 2 groups.
The 47% OS and 41% DFS at 3 years derived from our
experience in high-risk patients with hematologic disorders
(including 38% of patients with relapsed/refractory disease at
transplantation), with similar results in the dual SCT and
MUD SCT groups, are comparable to those reported in
previous registry studies [5,6,25,26]. The incidence of relapse
was comparable in the 2 groups. The relapse rate in our MUD
group was similar to that reported in 1 study of high-risk
patients [26], but that in our dual SCT group was higher
than reported in another study [14]. Two factors must be
considered related to the risk of relapse in the present study:
(1) a signiﬁcant incidence of active disease at the time of
transplantation (37% in thewhole series, 30% in theMUD SCT
group, and 40% in the dual SCTgroup) and (2) a low incidence
of cGVHD, eventually related to the use of ATG as part of the
conditioning regimen in both groups.
As reported previously [11-15], rapid neutrophil and
platelet recovery (14 and 27days, respectively) at the expense
of variable proportions of TPD cells superseded by permanent
CB engraftmentwas seen after dual SCT. Furthermore, days to
engraftment were similar in the 2 groups.
Using our current umbilical CB unit selection criteria
based primarily on cell dose, our CB graft failure rate (13%)
was similar to or even lower than rates reported previously
[27,28]. Nevertheless, other series with dual SCT reported CB
failure rates below 5% [12]. From the extensive experience
with CB transplantation, various mechanisms have been
associated with CB graft failure, including unit cell content,
degree of HLA mismatch, clonogenic capacity of CB progen-
itors, presence of host anti-HLA antibodies directed to CB
antigens, and host disease status [27-31]. In our series, the
poor postthaw CB viability was most likely related to CB graft
failure in the 3 cases, given that no other known causes for CB
failure were documented. Therefore, we believe that post-
thaw CB colony-forming unit assays should be used as
criteria for unit selection, as has been suggested previously
[31-33]. TPDmyeloid engraftment in 2 of these cases allowed
a second CB transplantation in 1 patient; however, both cases
had a dismal outcome with multiple infectious complica-
tions most likely related to poor immune reconstitution.
Rapid rescuemeasures should be started as soon as CB failure
is detected in this setting.
Early toxicity was associated with infectious complica-
tions independent of neutrophil engraftment, most
frequently viral hemorrhagic cystitis was apparently higher
in the dual SCT group compared with the MUD group (31%
versus 8%). The dual SCT group had a longer duration of
inpatient hospitalization in the ﬁrst 6 months, which could
be related to this viral complication, although the difference
between the 2 groups was not statistically signiﬁcant, likely
owing to the limited number of evaluable patients. The use of
high-dose steroids for GVHD prophylaxis is the most likely
cause of the higher rate of hemorrhagic cystitis in the dual
SCT group. Nonetheless, mortality associated with viral
complications was not signiﬁcantly higher in the dual SCT
group compared with the MUD group. The rates of other
signiﬁcant infectious complications also were similar in the 2
groups; of note, there were no differences in CMVreactivation and fungal infections. A high incidence of EBV
PTLD was recently reported in the dual SCT reduced-
intensity conditioning setting [29]; however, only 1 in 24
cases was documented in our series of dual SCT recipients.
The higher ATG doses used in the aforementioned study
could be a factor in this result.
GVHD is a major complication after allogeneic SCT,
resulting in variable degrees of morbidity and compromised
quality of life after transplantation, as well as higher rates of
NRM, especially after unrelated donor transplantation
[5,34,35]. We found signiﬁcantly lower rates of grade II-IV
aGVHD in the dual SCT group compared with the MUD
group, with similar DFS and OS in the 2 groups. Thus, this
strategy may be associated with signiﬁcantly less morbidity
from GVHD and its therapy, maintaining disease control in
surviving patients. This ﬁnding is of special interest for
patients with nonmalignant conditions, such as aplastic
anemia [23]. The observation of a graft-versus-tumor effect
and a low incidence of serious GVHD is consistent with
previous data on early and sustained recovery of natural
killer cells after CB transplantation and the recognition of the
eventual role of these cells as a potent antitumor effector
[15,36,37].
In the search for the ideal alternative donor source
and transplantation modality for patients lacking an HLA-
matched adult donor, procedures such as reduced-intensity
conditioning with unrelated double CB and partially
HLA-mismatched related BM are currently being evaluated
[38,39]. In our experience, single CB transplantation together
with the coinfusion of CD34þ cells from a third party HLA-
mismatched donor in high-risk patients offers time to
engraftment and survival rates comparable to those seen
with myeloablative 8/8 HLA-matched MUD transplantation,
with signiﬁcantly lower GVHD rates. The relatively small
number of patients included in this analysis requires that our
results be interpreted with caution. However, the homoge-
neous patient management in terms of both inclusion
criteria and clinical care, with all patients undergoing
transplantation in the same center at the same time
framewith the same follow-up, should outweigh the effect of
small sample size as a potential limitation. In contrast to
previous comparative studies including single CB trans-
plantations, the dual approach offers similar NRM rates as
MUD transplantation. Our results show that dual SCT
provides a valuable option for high-risk patients who lack
a matched adult donor or who require urgent trans-
plantation. Thus, this CB transplantation approach merits
broader exploration and validation in different hematologic
diseases and centers.
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